Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 2/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | RAD51 | Q06609 | 2/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 8/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CCR6 | P51684 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799897 | 1.00 | VCAM1 (0.51) | VCAM1PTGS2RAD51KAT2BMAPT | |
| SCHEMBL19639797 | 0.89 | VCAM1 (0.48) | VCAM1RAD51KAT2BMAPTKMT2A | |
| SCHEMBL1405745 | 0.80 | PTGS2 (0.51) | VCAM1PTGS2RAD51MAPTKMT2A | |
| SCHEMBL1405747 | 0.80 | PTGS2 (0.51) | VCAM1PTGS2RAD51MAPTKMT2A | |
| SCHEMBL11264895 | 0.79 | TSHR (0.53) | PTGS2KAT2BMAPTKMT2AMAPK1 | |
| SCHEMBL9848580 | 0.79 | ALDH1A1 (0.61) | PTGS2MAPTKMT2AMAPK1TDP1 | |
| SCHEMBL11264900 | 0.79 | TSHR (0.53) | PTGS2KAT2BMAPTKMT2AMAPK1 | |
| SCHEMBL8957884 | 0.79 | ALDH1A1 (0.61) | PTGS2MAPTKMT2AMAPK1TDP1 | |
| SCHEMBL125038 | 0.79 | VCAM1 (0.60) | VCAM1RAD51KAT2BMAPTKMT2A | |
| SCHEMBL29805549 | 0.79 | VCAM1 (0.60) | VCAM1RAD51KAT2BMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070072870-A2 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMECEUTICALS B.V. (NL) | 2007-03-29 | — | — | US | disclosed |
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
| US-6822100-B2 | REACTING N-SULFONYL-3-VINYLINDOLE WITH RUTHENIUM COMPLEX IN PRESENCE OF ETHYL DIAZOACETATE AND TOLUENE; PSYCHOLOGICAL, SEXUAL, AND EATING DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-23 | — | — | US | disclosed |
| US-6777437-B2 | ANTIDEPRESSANTS, ANXIOLYTIC AGENTS. SEXUAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-20040143003-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | MATTSON RONALD J (US) | 2004-07-22 | — | — | US | disclosed |
| EP-1373203-A1 | CYCLOPROPYLINDOLE DERIVATIVES AS SELECTIVE SEROTONIN REUPTAKE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030073849-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-17 | — | — | US | disclosed |
| WO-2002079152-A1 | CYCLOPROPYLINDOLE DERIVATIVES AS SELECTIVE SEROTONIN REUPTAKE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| US-3976639-A | Intermediates for indoles | HOFFMANN-LA ROCHE INC. (US) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072870-A2 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | HTR2C, HTR2A, HTR5A | VCAM1 3250/4885PTGS2 564/4885RAD51 3521/4885 |
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | HTR2C, HTR2A, HTR5A | VCAM1 3250/4885PTGS2 564/4885RAD51 3521/4885 |
| US-20040143003-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | HTR1A, HTR1D, TPH1 | VCAM1 2203/4885PTGS2 3189/4885RAD51 2543/4885 |
| US-20030073849-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | HTR5A, HTR1A, HTR2C | VCAM1 3423/4885PTGS2 2874/4885RAD51 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.